

Fibromyalgia - Pipeline Review, H2 2019

<https://marketpublishers.com/r/FAEBA0B04C6EN.html>

Date: November 2019

Pages: 111

Price: US\$ 2,000.00 (Single User License)

ID: FAEBA0B04C6EN

Abstracts

Fibromyalgia - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H2 2019, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by

Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 6, 4, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Fibromyalgia (Fibromyalgia Syndrome) - Overview
- Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Development
 - Pipeline Overview
 - Pipeline by Companies
 - Pipeline by Universities/Institutes
 - Products under Development by Companies
 - Products under Development by Universities/Institutes
 - Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
 - Fibromyalgia (Fibromyalgia Syndrome) - Companies Involved in Therapeutics Development
 - Aptinyx Inc
 - Astellas Pharma Inc
 - Grunenthal GmbH
 - H. Lundbeck AS
 - Innovative Med Concepts LLC
 - Intec Pharma Ltd
 - Jiangsu Hengrui Medicine Co Ltd
 - Luye Pharma Group Ltd
 - Tetra Bio-Pharma Inc
 - Teva Pharmaceutical Industries Ltd
 - Tonix Pharmaceuticals Holding Corp
 - Vitality Biopharma Inc
 - Fibromyalgia (Fibromyalgia Syndrome) - Drug Profiles (celecoxib + famciclovir) - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - ABX-1626 - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress

ASP-0819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

faxeladol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fremanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-03012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYX-2925 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palmidrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Agonize CB1 and CB2 for Chronic Pain and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize CB1 and CB2 for Fibromyalgia and Chronic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Type 1 Diabetes and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects

Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products

Fibromyalgia (Fibromyalgia Syndrome) - Product Development Milestones

Featured News & Press Releases

Oct 28, 2019: Aptinyx announces results of phase 2 fibromyalgia study of NYX-2925 have been selected for late-breaking presentation at the American College of Rheumatology Annual Meeting

Oct 03, 2019: Tonix Pharmaceuticals announces completion of long-term exposure studies in participants with PTSD to evaluate the Tolerability of TNX-102 SL 5.6 mg

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aptinyx Inc, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Astellas Pharma Inc, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Grunenthal GmbH, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by H. Lundbeck AS, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Innovative Med Concepts LLC, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Intec Pharma Ltd, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Luye Pharma Group Ltd, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tetra Bio-Pharma Inc, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Vitality Biopharma Inc, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H2 2019 (Contd..1), H2 2019

Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Aptinyx Inc

Astellas Pharma Inc

Grunenthal GmbH

H. Lundbeck AS

Innovative Med Concepts LLC

Intec Pharma Ltd

Jiangsu Hengrui Medicine Co Ltd

Luye Pharma Group Ltd

Tetra Bio-Pharma Inc

Teva Pharmaceutical Industries Ltd

Tonix Pharmaceuticals Holding Corp

Vitality Biopharma Inc

I would like to order

Product name: Fibromyalgia - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/FAEBA0B04C6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FAEBA0B04C6EN.html>